Switch theme
Sign up to access all valuation multiples
SD Biosensor Inc is an in vitro diagnostic company. It aims to contribute to the improvement of quality of life through rapid and accurate disease diagnosis. It is researching and developing quick diagnostics, immunodiagnostics, molecular diagnostics, blood glucose monitoring systems for self -testing.
1999
n/a
LTM Revenue n/a
LTM EBITDA n/a
$838M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SD Biosensor has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, SD Biosensor achieved revenue of $473M and an EBITDA of -$6.1M.
SD Biosensor expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SD Biosensor valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $447M | $473M | XXX | XXX | XXX |
| Gross Profit | $949M | $85.9M | XXX | XXX | XXX |
| Gross Margin | 212% | 18% | XXX | XXX | XXX |
| EBITDA | -$172M | -$6.1M | XXX | XXX | XXX |
| EBITDA Margin | -38% | -1% | XXX | XXX | XXX |
| Net Profit | $621M | -$319M | XXX | XXX | XXX |
| Net Margin | 139% | -67% | XXX | XXX | XXX |
| Net Debt | n/a | $74.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, SD Biosensor's stock price is KRW 9120 (or $6).
SD Biosensor has current market cap of KRW 1.09T (or $743M), and EV of KRW 1.23T (or $838M).
See SD Biosensor trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $838M | $743M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, SD Biosensor has market cap of $743M and EV of $838M.
SD Biosensor's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate SD Biosensor's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for SD Biosensor and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $838M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | -138.2x | XXX | XXX | XXX |
| P/E | -11.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 16.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSD Biosensor's NTM/LTM revenue growth is n/a
SD Biosensor's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, SD Biosensor's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate SD Biosensor's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for SD Biosensor and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -96% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 57% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SD Biosensor acquired XXX companies to date.
Last acquisition by SD Biosensor was XXXXXXXX, XXXXX XXXXX XXXXXX . SD Biosensor acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was SD Biosensor founded? | SD Biosensor was founded in 1999. |
| Where is SD Biosensor headquartered? | SD Biosensor is headquartered in South Korea. |
| Who is the CEO of SD Biosensor? | SD Biosensor's CEO is Mr. Hyo-Geun Lee. |
| Is SD Biosensor publicy listed? | Yes, SD Biosensor is a public company listed on KRX. |
| What is the stock symbol of SD Biosensor? | SD Biosensor trades under 137310 ticker. |
| When did SD Biosensor go public? | SD Biosensor went public in 2021. |
| Who are competitors of SD Biosensor? | Similar companies to SD Biosensor include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of SD Biosensor? | SD Biosensor's current market cap is $743M |
| What is the current revenue growth of SD Biosensor? | SD Biosensor revenue growth between 2023 and 2024 was 6%. |
| Is SD Biosensor profitable? | Yes, SD Biosensor is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
